Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Allogene Therapeutics Inc (ALLO)
NASDAQ:ALLO
RESEARCH TOOLSreports
Holding ALLO?
Track your performance easily
ALLO Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.78 - $5.78
Previous Close$2.16
Volume2.52M
Average Volume (3M)2.42M
Market Cap
$452.89M
Enterprise Value$246.46M
Total Cash (Recent Filing)$291.56M
Total Debt (Recent Filing)$85.14M
Price to Earnings (P/E)―
Beta2.43
Next Earnings
Feb 26, 2025EPS Estimate
-$0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.56
Shares Outstanding209,672,091
10 Day Avg. Volume3,007,065
30 Day Avg. Volume2,424,243
Standard Deviation0.21
R-Squared0.05
Alpha-0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.98
Price to Sales (P/S)4767.28
Price to Cash Flow (P/CF)-2.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-11.20K
Enterprise Value/Gross Profit2.59K
Enterprise Value/Ebitda-0.96
Forecast
1Y Price Target
$9.79Price Target Upside353.24% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
Allogene Therapeutics News
PremiumCompany Announcements
Allogene Therapeutics Advances CAR T Therapies
Bulls Say, Bears Say
Bulls Say
Financial StabilityA strong cash position of $403.4MM suggests financial stability for Allogene Therapeutics.
Innovative TherapiesALLO-329 was dosed in mice without any LD or irradiation, and achieved deep B cell depletion, which could be a key differentiating factor among cell therapies being developed for AID.
Research ProgressThe pivotal ALPHA3 trial is enrolling well with new sites coming onboard quickly, indicating strong progress in their research efforts.
Bears Say
Clinical DevelopmentThe discontinuation of the CLL program is seen as unfortunate due to slower-than-anticipated trial enrollment and the emergence of new alternative treatment options.
Financial PerformanceAllogene reported collaboration revenue of $0, which might indicate challenges in forming new partnerships or collaborations.
Safety ConcernsCabaletta’s grade 4 ICANS event is a concerning safety signal for the competitive landscape.
---
Ownership Overview
10.22% Insiders
25.78% Mutual Funds
27.66% Other Institutional Investors
25.42% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ALLO FAQ
What was Allogene Therapeutics Inc’s price range in the past 12 months?
Allogene Therapeutics Inc lowest stock price was $1.78 and its highest was $5.78 in the past 12 months.
What is Allogene Therapeutics Inc’s market cap?
Currently, no data Available
When is Allogene Therapeutics Inc’s upcoming earnings report date?
Allogene Therapeutics Inc’s upcoming earnings report date is Feb 26, 2025 which is in 51 days.
How were Allogene Therapeutics Inc’s earnings last quarter?
Allogene Therapeutics Inc released its earnings results on Nov 07, 2024. The company reported -$0.32 earnings per share for the quarter, beating the consensus estimate of -$0.333 by $0.013.
Is Allogene Therapeutics Inc overvalued?
According to Wall Street analysts Allogene Therapeutics Inc’s price is currently Undervalued.
Does Allogene Therapeutics Inc pay dividends?
Allogene Therapeutics Inc does not currently pay dividends.
What is Allogene Therapeutics Inc’s EPS estimate?
Allogene Therapeutics Inc’s EPS estimate is -$0.33.
How many shares outstanding does Allogene Therapeutics Inc have?
Allogene Therapeutics Inc has 209,672,090 shares outstanding.
What happened to Allogene Therapeutics Inc’s price movement after its last earnings report?
Allogene Therapeutics Inc reported an EPS of -$0.32 in its last earnings report, beating expectations of -$0.333. Following the earnings report the stock price went down -3.448%.
Which hedge fund is a major shareholder of Allogene Therapeutics Inc?
Among the largest hedge funds holding Allogene Therapeutics Inc’s share is PRIMECAP Management Co. It holds Allogene Therapeutics Inc’s shares valued at 16M.
---
Allogene Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.79 (353.24% Upside)
$9.79 (353.24% Upside)
Blogger Sentiment
Bullish
ALLO Sentiment 75%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 220.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $39.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 2.3%
Last 30 Days ▼ 2.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-35.13%
12-Months-Change
Fundamentals
Return on Equity
-54.15%
Trailing 12-Months
Asset Growth
-17.30%
Trailing 12-Months
Company Description
Allogene Therapeutics Inc
Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.
---
ALLO Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant advancements in clinical trials for both cancer and autoimmune diseases, showing promising efficacy and strong financial positioning. However, concerns about safety profiles and delays in regimen finalization pose challenges.Read More>---
ALLO Stock 12 Month Forecast
Average Price Target
$9.79
▲(353.24% Upside)
Technical Analysis
Best Analysts Covering ALLO
1 Year
1 Year Success Rate
4/19 ratings generated profit
1 Year Average Return
-23.79%
reiterated a buy rating 2 months ago
Copying John Newman's trades and holding each position for 1 Year would result in 21.05% of your transactions generating a profit, with an average return of -23.79% per trade.
---